l read they are developing a new drug called PIPE 307 that might be able to regrow myelin sheath and thereby restore damaged functions, anyone heard of this
This was on the MS Trusts facebook page.
PIPE-307 has shown promising results in studies in mice (not everything that works in mice will work in humans). Following a phase I study (a safety study in healthy people), it is now in the middle of a phase II clinical trial, which recruited its final participants earlier this year (https://www.neurologylive.com/…/enrollment-complete…). This will involve 168 people with relapsing remitting MS at sites across the US. According to the Clinical Trials website, the phase II trial is expected to finish in September 2025 (https://clinicaltrials.gov/study/NCT06083753)
If this shows that the drug acts as expected, there will need to be a larger phase III trial before it becomes more generally available.
NVG-291 has been shown to promote nervous system repair in animal versions of several conditions including spinal cord injury, stroke and MS. NervGen, the company developing NVG-291, have taken this forward with a proof-of-concept trial in Chicago that is currently recruiting people with a spinal cord injury. This will test that the treatment is safe in humans and that there are signs that bigger trials and trials in other conditions are justified.
NervGen, the company developing NVG-291, issues a press release about the trial in September (https://nervgen.com/nervgen-pharma-provides-update-on…/). The Clinical Trials website says this study is currently estimated to be completed in April 2026.
In research terms, both drugs are genuinely very interesting and have the potential to provide treatments that may slow MS down. In treatment terms, both are still experimental and any practical application is still several years away.
Simon, MS Trust Enquiry Service
4 Likes